Page last updated: 2024-12-11

dimethylaminochalcone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-dimethylaminochalcone: a fluorescent probe; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5377268
CHEMBL ID390381
MeSH IDM0066349

Synonyms (42)

Synonym
nsc-636916
nsc636916
(e)-3-(4-dimethylaminophenyl)-1-phenyl-prop-2-en-1-one
3-(4-(dimethylamino)phenyl)-1-phenyl-2-propen-1-one
1030-27-9
4-(dimethylamino)chalcone
4-(dimethylamino)benzalacetophenone
dimethylaminochalcone
nsc 40308
4-dimethylamino chalcone
nsc 229037
4-dimethylaminochalcone
nsc 360
2-propen-1-one, 3-(4-(dimethylamino)phenyl)-1-phenyl-
ccris 2223
ai3-22121
inchi=1/c17h17no/c1-18(2)16-11-8-14(9-12-16)10-13-17(19)15-6-4-3-5-7-15/h3-13h,1-2h3/b13-10+
pdkprwfmrvbcob-jlhyyagusa-
CHEMBL390381 ,
3-[4-(dimethylamino)phenyl]-1-phenyl-2-propen-1-one
AF-753/00287024
AKOS001586394
(2e)-3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-one
STK522212
unii-lql6uu7vc4
lql6uu7vc4 ,
3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-one
c17h17no
bdbm50440651
mfcd00168677
22965-98-6
(e)-4-(dimethylamino)chalcone
(2e)-3-[4-(dimethylamino)phenyl]-1-phenyl-2-propen-1-one #
trans-4-(dimethylamino)chalcone
PDKPRWFMRVBCOB-JLHYYAGUSA-N
3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1-one
(e)-3-(4-(dimethylamino)phenyl)-1-phenylprop-2-en-1-one
(e)-3-[4-(dimethylamino)phenyl]-1-phenylprop-2-en-1-one
XAA96598
CS-0320650
4-(dimethylamino)-trans-chalcone
D5312
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID283849Antifungal activity against Candida albicans Berhaut 62I in meat-pepton broth2007European journal of medicinal chemistry, Jan, Volume: 42, Issue:1
Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans.
AID306424Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 50 ug/ml assessed as reduction of relative light units2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives.
AID372906Antibacterial activity against Escherichia coli WF+2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted.
AID306425Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 100 ug/ml assessed as reduction of relative light units2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives.
AID372908Antibacterial activity against Staphylococcus aureus Rosenbach 209 after 24 hrs by serial dilution method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted.
AID372907Antibacterial activity against Staphylococcus aureus Rosenbach 209 after 48 hrs by agar well diffusion method2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted.
AID1543105Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in LLC-MK2-ATCC CCL7 cells assessed as reduction in parasite growth incubated for 24 hrs by Alamar blue dye based assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID1543107Selectivity index, ratio of CC50 for cytotoxicity in mouse NCTC-929 cells to EC50 for Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes infected in LLC-MK2-ATCC CCL7 cells2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID1543106Cytotoxicity in mouse NCTC-929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12
Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID283847Antifungal activity against Candida albicans Berhaut 62I after 24 hrs2007European journal of medicinal chemistry, Jan, Volume: 42, Issue:1
Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans.
AID283848Growth inhibition of Candida albicans Berhaut 62I by agar cup method2007European journal of medicinal chemistry, Jan, Volume: 42, Issue:1
Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (17.65)18.7374
1990's2 (11.76)18.2507
2000's5 (29.41)29.6817
2010's6 (35.29)24.3611
2020's1 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]